Company Analysis
Sign in

Cartesian Therapeutics, Inc. (RNAC)

Nasdaq: RNAC · Pharmaceutical Preparations · Frederick, MD · filing with the SEC since 2009
Full chart Alerts Compare
Grade3.2
◀ Past 3.6● Present 2.5▶ Future 3.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

38 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Cartesian Therapeutics, Inc.’s names, not what it holds today.

Patents granted
38
38 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 1 in 2024 and 3 in 2023
Applications published
145
5 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals10
Biotechnology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Selecta Biosciences, Inc. a former name
US, as the owner printed on each patent
32 granted
116 published
Cartesian Therapeutics Inc. its own name
US, as the owner printed on each patent
6 granted
11 published
Selecta Biosciences, Inc. a former name
named as the applicant on its applications, in US
0 granted
17 published
Cartesian Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,508,249Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxisPharmaceuticalsCartesian Therapeutics Inc.
Nov 18, 202512,472,167Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivityPharmaceuticalsCartesian Therapeutics Inc.
Jan 14, 202512,194,078Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressantPharmaceuticalsCartesian Therapeutics Inc.
Jun 4, 202411,999,773Anti-BCMA chimeric antigen receptorsBiotechnologyCartesian Therapeutics Inc.
Oct 10, 202311,779,641Tolerogenic synthetic nanocarriers for allergy therapyPharmaceuticalsSelecta Biosciences, Inc.
Aug 8, 202311,717,569Tolerogenic synthetic nanocarriersPharmaceuticalsSelecta Biosciences, Inc.
Apr 25, 202311,633,422Methods and compositions for attenuating anti-viral transfer vector immune responsesPharmaceuticalsSelecta Biosciences, Inc.
Aug 30, 202211,426,451Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressantPharmaceuticalsSelecta Biosciences, Inc.
Apr 12, 202211,298,342Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivityPharmaceuticalsSelecta Biosciences, Inc.
Feb 1, 202211,235,057Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responsesPharmaceuticalsSelecta Biosciences, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 5, 20252025/0177360METHODS RELATED TO ADMINISTERING IMMUNOSUPPRESSANTS AND THERAPEUTIC MACROMOLECULES AT A REDUCED PHARMACODYNAMICALLY EFFECTIVE DOSEPharmaceuticalsCartesian Therapeutics Inc.
May 15, 20252025/0152561METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOCARRIERS WITH RAPAMYCIN IN A STABLE, SUPER-SATURATED STATEPharmaceuticalsCartesian Therapeutics Inc.
Apr 3, 20252025/0108094METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANTPharmaceuticalsCartesian Therapeutics Inc.
Mar 20, 20252025/0090451FORMULATIONS AND DOSES OF PEGYLATED URICASEPharmaceuticalsCartesian Therapeutics Inc.
Feb 20, 20252025/0057756FORMULATIONS AND DOSES OF PEGYLATED URICASEPharmaceuticalsCartesian Therapeutics Inc.
Oct 24, 20242024/0350462METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCEPharmaceuticalsSelecta Biosciences, Inc.
Oct 17, 20242024/0344030MULTIPROTEIN-ENGINEERED CELLS SECRETING A MULTISPECIFIC ANTIBODYBiotechnologyCartesian Therapeutics Inc.
Sep 5, 20242024/0294600ANTI-BCMA CHIMERIC ANTIGEN RECEPTORSBiotechnologyCartesian Therapeutics Inc.
Aug 8, 20242024/0261396TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPYPharmaceuticalsSelecta Biosciences, Inc.
May 16, 20242024/0156955TOLEROGENIC SYNTHETIC NANOCARRIERSPharmaceuticalsSelecta Biosciences, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 10 · Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RNAC · research, not advice